SC junks BCCI, Riju Raveendran's plea on settlement for Byju's
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
The Supreme Court on Monday upheld an order rejecting the appeals of the BCCI and Byju's co-founder Riju Raveendran seeking withdrawal of insolvency proceedings against his company.A bench comprising Justices J B Pardiwala and R Mahadevan dismissed the appeals filed by the Board of Control for Cricket in India (BCCI) and Raveendran challenging the National Company Law Appellate Tribunal ( NCLAT ) verdict on April 17.BCCI and Raveendran had previously challenged an order of the Bengaluru bench of the National Company Law Tribunal , which on February 10 directed to place their settlement offer before the new Committee of Creditors (CoC), in which US-based Glas Trust , the trustee for lenders to which Byju's owes USD 1.2 billion, is a member.A two-member Chennai bench of the NCLAT comprising Justice Rakesh Kumar Jain and Jatindranath Swain upheld the directions passed by the NCLT and said the settlement proposal was filed after the formation of CoC, hence as the provisions of Section 12 A of the Insolvency & Bankruptcy Code, it requires the approval of the lender's body.Both BCCI and Raveendran contended since the application under Section 12A was filed before the constitution of the CoC, the provisions of Section 12A coupled with Regulation 30A(1)(a) shall apply and not Regulation 30A(1)(b).Section 12 A of IBC prescribes an exit route from insolvency. It mandates that NCLT may allow the withdrawal of insolvency initiated by any financial or operational creditor under Sections 7,9 or section 10, based on an application made with the approval of 90 per cent voting share of the CoC.Regulation 30A(1)(a) deals with the provision of filing Section 12 A proceedings through the interim resolution profession before formation of CoC whereas 30A(1)(b) deals with provision of filing after formation of CoC.The BCCI and Byju's contended Form FA, which is an application for withdrawal of Corporate Insolvency Resolution Process (CIRP), was submitted before the formation of CoC of Byju's.However, rejecting the plea NCLAT said, "Form FA, admittedly having been filed on November 14, 2024, is post (formation of) CoC.""If the application under Section 12A is filed under Regulation 30A(1)(a) before the constitution of CoC then Section 12A which mandates the approval of such application for withdrawal by 90 per cent voting share of the CoC shall not apply but if the application is filed after the constitution of the CoC then the provisions of Section 12A shall apply with full force," said NCLAT.CIRP against Byju's was initiated on July 16, 2024 by NCLAT admitting a Rs 158.90 crore claim from BCCI as an operational creditor of edtech major. An IRP was appointed also by the NCLT in this matter.Later, a settlement was arrived between the parties and Raveendran approached NCLAT.The appellate tribunal set aside the insolvency proceedings against Byju's on August 2, 2024 after approving dues settlement with the BCCI, which had entered into a Team Sponsor Agreement with the cricket body in 2019.This was challenged by Glas Trust before the Supreme Court.Glas Trust, a financial creditor, also filed a separate petition before NCLT seeking resolution of its debt of USD 984.3 million (approximately Rs 8,200 crore).The apex court on October 23, 2024, set aside the NCLAT order staying the CIRP against Think & Learn, which owns edtech brand Byju's and asked BCCI to approach NCLT for the settlement.Although BCCI submitted Form FA to the Interim Resolution Professional (IRP) on August 16, 2024, it had instructed the IRP to file it only after the resolution of an appeal pending before the Supreme Court.Raveendran contended before NCLAT there was a delay on the part of the IRP in filing the withdrawal form.The NCLAT, however, rejected the plea.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
24 minutes ago
- Business Standard
India-UK trade deal boosts access for Indian medical devices in Britain
The India-UK trade pact has incorporated a mutual recognition agreement framework to facilitate smoother entry of medical devices certified by domestic regulatory agencies into the British market, an official said on Tuesday. The framework will help Indian manufacturers expand market share in the UK vis-a-vis its global competitors like China, Brazil, and Vietnam who face non-preferential duty. "The free trade agreement includes a mutual recognition agreement framework allowing medical devices certified by the Central Drugs Standard Control Organisation (CDSCO) or the Indian Certification of Medical Devices (ICMED) to access the UK market more freely," the official said. Medical devices and instruments will be exported to the UK at zero tariffs, down from the current duty range of 2 per cent to 6 per cent, benefiting Indian manufacturers of surgical and diagnostic equipment. The UK medical devices market was valued at USD 32 billion in 2024 and is projected to reach USD 69 billion by 2035, growing at a CAGR of 7.19 per cent, representing a significant opportunity for Indian medical device manufacturers, the official said. A bilateral regulatory cooperation framework will also be pursued between CDSCO and MHRA (Medicines and Healthcare products Regulatory Agency) potentially taking the form of a Mutual Recognition Agreement (MRA). "The agreement will incorporate provisions for joint inspections, data sharing, harmonization of technical documentation, and training programmes between Indian and UK regulators, which will help build confidence and trust in each other's regulatory frameworks, thereby enhancing market access for our exports," the official said. India remains committed to a fair, balanced, and mutually beneficial agreement and is engaging with the UK to consider pathways for regulatory cooperation, including recognition of CDSCO approvals. Further to prevent routing of third country goods via the UK into India, there are provisions for strong Rules of Origin (RoO) in the comprehensive economic and trade agreement, which define the origin of a product and determine whether it qualifies for preferential tariffs. The combination of rigorous RoO, digital certificate of origin systems, and customs monitoring will ensure that only legitimate products -- made or significantly transformed in the FTA partner -- benefit from tariff concessions.
The Hindu
24 minutes ago
- The Hindu
U.S. team to visit India on August 25 for next round of talks for trade pact
The U.S. team will visit India on August 25 for the next round of negotiations for the proposed bilateral trade agreement between the two countries, an official said on Tuesday (July 29, 2025). The official added that the two sides continue to be engaged in an interim trade deal as the August 1 deadline is approaching. August 1 marks the end of the suspension period of tariffs imposed by U.S. President Donald Trump on dozens of countries, including India (26 per cent). "The US team is visiting for the sixth round of talks," the official said. India and the U.S. teams concluded the fifth round of talks for the agreement last week in Washington. India's chief negotiator and Special Secretary in the Department of Commerce, Rajesh Agrawal and Assistant U.S. Trade Representative for South and Central Asia Brendan Lynch held the deliberations. These deliberations are important as both sides are looking at finalising an interim trade deal before August 1. On April 2 this year, Mr. Trump announced high reciprocal tariffs. The implementation of high tariffs was immediately suspended for 90 days till July 9 and later until August 1, as America is negotiating trade deals with various countries. Agri sector concerns India has hardened its position on the U.S. demand for duty concessions on agri and dairy products. New Delhi has, so far, not given any duty concessions to any of its trading partners in a free trade agreement in the dairy sector. Certain farmers' associations have urged the government not to include any issues related to agriculture in the trade pact. India is seeking the removal of this additional tariff (26 per cent). It is also looking at the easing of tariffs on steel and aluminium (50 per cent) and the auto sector (25 per cent). These issues are an important part of the trade pact negotiations. Against these, India has reserved its right under the WTO (World Trade Organization) norms to impose retaliatory duties. The country is also seeking duty concessions for labour-intensive sectors, such as textiles, gems and jewellery, leather goods, garments, plastics, chemicals, shrimp, oil seeds, grapes, and bananas, in the proposed trade pact. On the other hand, the U.S. wants duty concessions on certain industrial goods, automobiles, especially electric vehicles, wines, petrochemical products, agri goods, dairy items, apples, tree nuts, and genetically modified crops. The two countries are looking to conclude talks for the first tranche of the proposed bilateral trade agreement (BTA) by fall (September-October) this year. Before that, they are looking for an interim trade pact. India's merchandise exports to the U.S. rose 22.8 per cent to USD 25.51 billion in the April-June quarter this financial year, while imports rose 11.68 per cent to USD 12.86 billion.
Hans India
24 minutes ago
- Hans India
Jubilant Pharmova clocks nearly 79 pc drop in net profit to Rs 103 crore
Mumbai: Jubilant Pharmova Limited on Tuesday reported a sharp fall of 78.6 per cent in its net profit to Rs 103 crore for the first quarter of the financial year 2025-26 (Q1 FY26), compared to Rs 482 crore in the same quarter previous year (Q1 FY25). Revenue for the quarter rose nearly 9 per cent to Rs 1,900 crore from Rs 1,732 crore a year ago, according to its stock exchange filing. The company's EBITDA increased 11 per cent to Rs 267.1 crore, up from Rs 240.7 crore in the year-ago period. Margins also saw a slight improvement, standing at 14.2 per cent compared to 14 per cent previous year. Total expenses during the quarter grew to Rs 1,758 crore from Rs 1,642 crore in the same period of FY25, the company stated in its regulatory filing. Around 2 p.m., the shares of the company were trading at Rs 1,147.3, down by Rs 26.9 or 2.29 per cent on the National Stock Exchange (NSE). In last five days, the shares has delivered a negative return of over Rs 40 or 3.37 per cent to its investors. Jubilant Pharmova is Uttar Pradesh-based global pharmaceutical company with operations in over 50 countries, including the US, Europe, Canada, Japan, and Australia. It operates through three main business segments -- Pharmaceuticals, Drug Discovery & Development Solutions, and Proprietary Novel Drugs. Its portfolio includes radiopharmaceuticals, allergy therapy products, generic formulations, active pharmaceutical ingredients, and sterile injectables. The company also provides contract manufacturing services for sterile and non-sterile products and offers contract research and development solutions through its CRDMO business. In addition to its business operations, Jubilant Pharmova runs corporate social responsibility initiatives, including sustainability projects and education programmes in government schools. In recent years, the company has expanded its research capabilities, including the expansion of its Chemistry Innovation Research Centre in Greater Noida. It has also launched new products like the RUBY Rubidium Elution System and RUBY-FILL for mobile medical use.
